CLOSE
MENU
Chordia Therapeutics Inc.
News
サブ-ナビゲーション
Company
Science
現在位置:
News
Career
Contact
Privacy Policy
Term of use
Sitemap
News
Sep 15, 2023
Selected for the latest edition of "100 Amazing Venture Businesses" in 2023
(184KB)
Sep 15, 2023
Nominated as a finalist of the Informa Pharma Intelligence Awards Japan 2023
(267KB)
Jun 01, 2023
Dosing of CLK Inhibitor CTX-712 Starts in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome in the U.S.
(166KB)
May 17, 2023
Fujitsu, Kyoto University, and Chordia Therapeutics Launch AI Trials to Discover Biomarkers for New Cancer Drugs
(147KB)
Feb 17, 2023
Initiated Phase 1/2 Study of CTX-712, a CLK Inhibitor, in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome in the U.S.
(301KB)
Feb 16, 2023
Receives Development Milestone Payment of CTX-177 (ONO-7018), a MALT1 Inhibitor, According to License Agreement with Ono Pharmaceutical
(238KB)
Dec 12, 2022
Announces Interim Results of CLK Inhibitor CTX-712 and MALT-1 Inhibitor CTX-177 at the 2022 ASH Annual Meeting.
(284KB)
Nov 21, 2022
Published 5th Financial Report
(496KB)
Oct 03, 2022
Chordia Therapeutics Director and Statutory Auditor Appointments
(263KB)
Sep 08, 2022
Chordia Named “Ministry of Education, Culture, Sports, Science and Technology (MEXT) Award” at Academic Startups 2022
(270KB)
Aug 29, 2022
Chordia’s Licensee Ono Pharmaceutical Co., Ltd. Initiated a Phase 1 Study of ONO-7018 (CTX-177), a MALT1 Inhibitor, in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia in the U.S.
(281KB)
Jun 07, 2022
Announces Interim Results of the Phase 1 Clinical Trial of CLK Inhibitor CTX-712 at the 2022 ASCO Annual Meeting
(304KB)
Jun 07, 2022
Concludes Basic Agreement on Collaboration with Shionogi Pharma Co., Ltd.
(216KB)
May 19, 2022
Concludes Basic Agreement on Business Tie Up with MEDIPAL HOLDINGS CORPORATION
(232KB)
May 19, 2022
Raises Approximately 4 Billion JPY in Series C Financing, Achieving a Cumulative Total of Approximately 8.2 Billion JPY
(215KB)
May 16, 2022
Featured as a Cover Story in Startup City Magazine’s “Top 10 Japanese Startups 2022”
(2,325KB)
Apr 07, 2022
Nominated as a Finalist of the Informa Pharma Intelligence Awards Japan 2022
(302KB)
Dec 03, 2021
Published 4th financial report
(660KB)
Sep 24, 2021
Assignment of Statutory Auditor
(92KB)
Mar 03, 2021
Interview with CEO Miyake Published in Scrip
Feb 04, 2021
Interview with CSO Morishita Published in AnswersNews
Dec 15, 2020
Notice of License Agreement
(121KB)
Oct 25, 2019
Chordia Therapeutics Announced the Appointment of CMO & CSO
(181KB)
Mar 29, 2019
Chordia Therapeutics Raises Around $27 Million in Series B Financing
(212KB)
Jan 10, 2019
Published Our Article in Forbes JAPAN
Oct 12, 2018
1st Results Presentation of the AMED ACT-M
(846KB)
Nov 30, 2017
Chordia Therapeutics Raises Around $11 Million in Series A Financing
(562KB)
Nov 22, 2017
Launch of Chordia Therapeutics
(562KB)
VIEW ALL
マルチ3はありません
ページの先頭へ
ページの先頭へ
menu
gnavi-box